Geography Covered
- Global coverage
Ocular Hypertension: Understanding
Ocular Hypertension: Overview
Ocular hypertension is a condition characterized by elevated pressure inside the eye, which occurs when the aqueous humor, a fluid responsible for nourishing the eye and maintaining its shape, doesn't drain properly. Although individuals with ocular hypertension often experience no noticeable symptoms or changes to their vision, the condition can increase the risk of developing glaucoma, a more serious eye disorder that causes structural damage and potential vision loss. While ocular hypertension does not always progress to glaucoma, regular monitoring by an eye care professional is essential to detect any early signs of damage and manage the condition effectively. Lifestyle factors, such as diet and stress levels, may also play a role in managing eye pressure, though medication or other treatments may be necessary for some individuals. Early intervention can help prevent long-term damage and preserve vision.Increased intraocular pressure can result from either an excess of fluid entering the eye or a reduced ability of the eye to drain fluid properly. Several conditions can interfere with the normal drainage of aqueous humor, leading to elevated pressure. One such cause is uveitis, an inflammation of the middle portion of the eye, which can affect fluid drainage. Pigment dispersion syndrome occurs when tiny pigment particles from the iris float around inside the eye, potentially blocking the trabecular meshwork, the primary drainage system for the aqueous humor. Pseudoexfoliation syndrome, characterized by the buildup of microscopic protein fibers within the eye, can also obstruct fluid flow. Other causes include the presence of tumors or large cataracts that block drainage pathways, damage caused by eye injury or surgery, and certain medications, particularly corticosteroids. Additionally, chronic angle-closure, in which the iris blocks the trabecular meshwork, can hinder the outflow of aqueous humor, increasing intraocular pressure.
Several factors can increase the risk of developing ocular hypertension. Individuals aged 40 or older are at greater risk, as are those with a family history of ocular hypertension or glaucoma. People with severe nearsightedness (myopia) or farsightedness (hyperopia) are also more prone to elevated eye pressure. Additionally, conditions like diabetes and high blood pressure can contribute to higher risk. Eye injuries, previous eye surgeries, or eye injections may also increase susceptibility. Long-term use of steroid medications is a known risk factor, as are specific eye conditions such as pigment dispersion syndrome and pseudoexfoliation syndrome. Certain medications, like topiramate, may also raise the likelihood of developing ocular hypertension.
Ocular hypertension doesn't always require treatment, but doctors assess the patient's risk of developing glaucoma over the next five to ten years to determine the best approach. If the risk is moderate to high, treatment is usually recommended to prevent damage to the optic nerve. If the risk is low, doctors typically prefer to monitor the condition instead. When treatment is necessary, the most common approach is prescribing eye drops to lower intraocular pressure by 20% to 25%. These drops can include prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and netarsudil (a rho-kinase inhibitor). In some cases, laser surgery may be considered to help reduce intraocular pressure, although most patients won't require this intervention.
"Ocular Hypertension- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.Ocular Hypertension Emerging Drugs Chapters
This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Ocular Hypertension Emerging Drugs
- Sepetaprost: Santen Pharmaceutical
- NCX 470: Nicox Ophthalmics, Inc.
- QLS-111: Qlaris Bio, Inc.
- H-1337: Allysta Pharmaceuticals
- RTC-1119: Ripple Therapeutics
Ocular Hypertension: Therapeutic Assessment
This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Ocular Hypertension
- There are approx. 50+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Santen Pharmaceutical.
Phases
The report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Ocular Hypertension: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.Ocular Hypertension Report Insights
- Ocular Hypertension Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ocular Hypertension Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ocular Hypertension drugs?
- How many Ocular Hypertension drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ocular Hypertension and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Santen Pharmaceutical
- Nicox Ophthalmics, Inc.
- Allysta Pharmaceuticals
- Qlaris Bio, Inc
- Ripple Therapeutics
- Laboratoires Thea
- Ocular Therapeutix, Inc.
- Otsuka Beijing Research Institute
- Alcon Research
- AbbVie
- Glaukos Corporation
- MediPrint Ophthalmics
- Ocuphire Pharma
Key Products
- Sepetaprost
- NCX 470
- QLS-111
- H-1337
- RTC-1119
- T4090
- OTX-TIC
- OPC-1085EL
- AR-17043
- AGN-193408 SR
- iDose TREX
- LL-BMT1
- Nyxol
This product will be delivered within 2-4 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Santen Pharmaceutical
- Nicox Ophthalmics, Inc.
- Allysta Pharmaceuticals
- Qlaris Bio, Inc
- Ripple Therapeutics
- Laboratoires Thea
- Ocular Therapeutix, Inc.
- Otsuka Beijing Research Institute
- Alcon Research
- AbbVie
- Glaukos Corporation
- MediPrint Ophthalmics
- Ocuphire Pharma